LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ

LIGAND PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$297.28+1.74 (+0.59%)

Close on Oct 19, 2026

Market cap: $6.49B
P/E (TTM): 31.6
Dividend yield: –

LIGAND PHARMACEUTICALS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2007 2007-12-31
Revenue	268	167	131	196	242	164	120	251	141	109	72	65	49	31	30	24	39	–
Cost of Revenue	–	–	–	–	–	–	–	6.34	5.37	5.57	5.81	9.14	5.73	3.60	4.91	–	–	–
Gross Profit	–	–	–	–	–	–	–	245	136	103	66	55	43	28	25	–	–	–
Research & Development	81	21	25	36	32	41	56	28	27	21	11	9.75	9.27	11	10	22	40	–
General & Administrative	92	79	53	70	47	60	42	38	29	28	25	23	18	16	15	13	15	–
Operating Income	41	-23	12	3.04	104	38	807	164	68	44	27	20	15	0.19	-0.88	-29	-9.97	–
Interest Expense	4.72	3.04	0.66	1.80	20	27	36	48	13	13	–	4.86	2.08	2.92	2.51	0.06	0.27	–
Interest & Investment Income	14	8.06	7.71	2.05	0.89	8.08	28	14	2.06	–	–	–	–	–	0.03	0.44	0.59	–
Income from Equity Investments	0	-7.01	-1.83	0	0	–	2.89	48	1.11	-23	-5.14	0	0	–	–	–	–	–
Other Non-Operating Income	118	25	52	33	-32	-36	-10	9.60	-11	-36	8.00	-8.32	-5.74	-4.06	-2.68	14	0.10	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	-0.02	0.01	-0.02	-0.46	5.30	0.50	–
Gain (Loss) on Investments	18	75	46	29	-5.26	-17	1.05	50	-2.05	-23	–	–	–	–	-0.01	0.61	0.23	–
Gain (Loss) on Sale of Assets	0	0	2.12	0	0	17	0	0	0	1.10	0	0	–	–	–	–	–	–
Pretax Income	159	2.52	64	36	72	1.29	797	173	57	7.96	35	11	9.21	-3.87	-3.56	-15	-9.87	–
Income Tax Expense	35	6.55	9.84	41	-4.15	-5.31	167	30	45	10	-192	0.41	0.37	-1.19	-13	-2.62	-1.54	–
Income from Continuing Operations	124	-4.03	54	-5.22	76	6.60	–	143	13	-2.37	227	11	8.83	-2.67	9.71	-13	-8.34	–
Income from Discontinued Operations	–	–	-1.67	-28	-19	-9.58	–	–	–	–	–	0	2.59	2.15	0.00	2.41	–	–
Net Income incl. Noncontrolling Interests	–	–	–	-33	57	-2.99	629	143	13	-1.64	227	11	11	-0.53	–	–	–	–
Minority Interest in Earnings	–	–	–	–	–	–	–	–	0	0	2.38	-1.13	0	0	–	–	–	–
Net Income	124	-4.03	52	-33	57	-2.99	629	143	13	-1.64	230	12	11	-0.53	9.72	-10	-1.95	–
EPS (Basic)(per share)	6.44	-0.22	3.02	-1.98	3.44	-0.18	33.13	6.77	0.60	-0.08	11.61	0.59	0.56	-0.03	0.49	-0.53	-0.10	–
EPS (Diluted)(per share)	6.13	-0.22	2.94	-1.98	3.31	-0.18	31.85	5.96	0.53	-0.08	10.83	0.56	0.55	-0.03	0.49	-0.53	-0.10	–
Shares Outstanding (Basic, Weighted)(shares)	19	18	17	17	17	16	19	21	21	21	20	20	20	20	20	20	19	–
Shares Outstanding (Diluted, Weighted)(shares)	20	18	18	17	17	17	20	24	23	21	21	21	21	20	20	20	19	–
Dividend per Share(per share)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.50
EBITDA	75	13	48	55	155	63	825	177	79	55	30	22	18	2.92	1.91	-27	-5.33	–
Net Interest Income	–	–	–	–	–	–	–	–	-11	-12	-12	-4.86	-2.08	-2.92	-2.30	0.38	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 32.6%
Net margin: 67.9%
Return on equity, FY2025: 13.5%

Financial strength

Current ratio: 31.18
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2154.0%

Valuation

P/E ratio: 31.6
Price to sales: 22.34
Price to book: 6.71
Dividend yield: –